查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
脊髓性肌萎缩症 (SMA) 治疗全球市场规模和预测：按产品、按疾病类型、按分销渠道、按地区，2022-2029 年
市场调查报告书
商品编码
1215324

脊髓性肌萎缩症 (SMA) 治疗全球市场规模和预测：按产品、按疾病类型、按分销渠道、按地区，2022-2029 年

Global Spinal Muscular Atrophy Treatment Market Size study & Forecast, by Product, by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021 年全球脊髓性肌萎缩症治疗市场价值约 38.8 亿美元，在 2022-2029 年预测期内以超过 18.6% 的健康增长率增长 据预测

脊髓性肌萎缩症 (SMA) 是一种遗传性疾病，会逐渐破坏脊髓和脑干中的运动神经元。 它还影响重要的骨骼肌活动，如呼吸、行走、说话和吞嚥，导致肌肉无力和萎缩。 对新疗法的认识提高、政府支持增加以及医疗保健成本上升是推动全球市场增长的主要因素。

脊髓性肌萎缩症患病率呈上升趋势，这与全球市场需求直接相关。 根据国家罕见病组织 (NORD) 的估计，全世界大约每 10,000 人中就有 1 人患有脊髓性肌萎缩症 (SMA)。 同样，据脊髓性肌萎缩症基金会称，预计该疾病将影响全球 6,000 至 10,000 名新生儿中的 1 名。 因此，这种疾病发病率的增加对市场需求做出了积极贡献，从而推动了市场增长。 此外，新的高效产品的推出和研发投资的增加在预测期内创造了各种机会。 然而，与获批产品相关的高成本和熟练专业人员的短缺限制了整个 2022-2029 年预测期内的市场增长。

全球脊髓性肌萎缩症治疗市场研究考虑的主要区域包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于治疗产品支出的增加和人口中 SMA 疾病发病率的上升，北美在收入方面占据了市场主导地位。 另一方面，由于目标人口的增长、医疗保健服务支出的增加以及市场空间主要参与者的地域扩张等因素，预计亚太地区在预测期内将以最高的复合年增长率增长。

本报告中包含的主要市场参与者是：

  • 百健
  • 诺华公司
  • Ionis Pharmaceuticals, Inc.
  • Biohaven 製药公司
  • F. Hoffmann-La Roche
  • 细胞动力学
  • 标量岩
  • PTC 治疗
  • NMD 製药公司
  • 安斯泰来製药公司
市场的

近期发展。

  • 2022 年 1 月，百健（Biogen）和 Ionis Pharmaceuticals 签订了开发另一种实验药物 BIIB115 的许可协议，BIIB115 是一种反义寡核甘酸，旨在治愈 SMA 患者。 BIIB115是临床前试验中的实验药物。 该协议的目的是扩大百健（Biogen）公司的 SMA 治疗产品组合。
  • 2019 年 5 月，诺华公司宣布 Zolgensma (onasemnogene abeparvovec-xioi) 获得美国 FDA 批准，成为首个也是唯一一个用于小儿脊髓性肌萎缩症 (SMA) 患者的基因疗法。底部。

全球脊髓性肌萎缩症药物市场研究范围。

  • 历史数据：2019-2020-2021
  • 基本估算年份：2021 年
  • 预测期间：2022-2029
  • 报告范围利润预测、公司排名、竞争格局、增长因素和趋势
  • 涵盖的细分市场产品类型、疾病类型、分销渠道、地区
  • 区域覆盖范围 北美；欧洲；亚太地区；拉丁美洲；世界其他地区
  • 自定义范围 报告自定义是免费的（最多 8 小时的分析师工作）。 添加或更改国家、地区或细分范围*。

这项研究的目的是定义近年来各个细分市场和国家的市场规模，并预测他们在未来几年的价值。 该报告旨在捕捉被调查国家工业的定性和定量方面。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。

按产品

  • 努西内森
  • Onasemnogen Abeparvovec

按疾病类型

  • 1 型 SMA
  • 2 型 SMA
  • 其他

按销售渠道

  • 医院药房
  • 零售店
  • 其他

按地区

  • 北美
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 意大利
  • 净资产收益率
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 韩国
  • 下包
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 罗拉
  • 世界其他地方

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年各细分市场的全球市场估计和预测
    • 脊髓性肌萎缩症治疗市场：按地区划分，2019-2029 年
    • 脊髓性肌萎缩症市场：按产品分类，2019-2029 年
    • 脊髓性肌萎缩症治疗市场：按疾病类型分类，2019-2029 年
    • 脊髓性肌萎缩症市场：分销渠道，2019-2029 年
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章脊髓性肌萎缩症药物的全球市场定义和范围

  • 调查的目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第 3 章全球脊髓性肌萎缩症治疗市场动态

  • 脊髓性肌萎缩症药物市场影响分析（2019-2029）
    • 市场驱动因素
      • 提高对新疗法的认识
      • 脊髓性肌萎缩症患病率上升
    • 市场挑战
      • 与获批产品相关的高成本
      • 缺乏熟练的专业人员
    • 市场机会
      • 推出具有高效能的新产品
      • 扩大研发投资

第 4 章全球脊髓性肌萎缩症治疗市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 顶级投资机会
  • 关键成功策略
  • 行业专家的展望
  • 分析师的结论和建议

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章全球脊髓性肌萎缩症治疗市场：副产品

  • 市场概况
  • 全球脊髓性肌萎缩症治疗市场：按产品分类的性能潜力分析
  • 2019-2029 年按产品分列的脊髓性肌萎缩症治疗全球市场估计和预测
  • 脊髓性肌萎缩症治疗市场，细分分析
    • 努西内森
    • Onasemnogen Abeparvovec

第 7 章：脊髓性肌萎缩症治疗药物的全球市场，按疾病类型分类

  • 市场概况
  • 全球脊髓性肌萎缩症治疗市场：按疾病类型进行性能潜力分析
  • 2019-2029 年全球脊髓性肌萎缩症治疗市场、按疾病类型估计和预测
  • 脊髓性肌萎缩症治疗市场，细分分析
    • 1 型 SMA
    • 2 型 SMA
    • 其他

第 8 章脊髓性肌萎缩症药物的全球市场：按分销渠道

  • 市场概况
  • 全球脊髓性肌萎缩症药物市场：按分销渠道进行的性能潜力分析
  • 2019-2029 年全球脊髓性肌萎缩症治疗药物市场、分销渠道估计和预测
  • 脊髓性肌萎缩症治疗市场，细分分析
    • 医院药房
    • 零售药房
    • 其他

第 9 章脊髓性肌萎缩症药物的全球市场：区域分析

  • 脊髓性肌萎缩症药物市场，按地区划分的市场概况
  • 北美
    • 美国
      • 2019-2029 年按产品估算和预测
      • 按疾病类型估算和预测，2019-2029 年
      • 2019-2029 年各分销渠道的估计和预测
    • 加拿大
  • 欧洲脊髓性肌萎缩症药物市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区脊髓性肌萎缩症治疗市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲脊髓性肌萎缩症治疗市场概况
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 世界其他地方

第 10 章衝突信息

  • 顶级市场策略
  • 公司简介
    • 百健
      • 主要信息
      • 概览
      • 财务信息（取决于数据可用性）
      • 产品概述
      • 近期趋势
    • Novartis AG
    • Ionis Pharmaceuticals Inc.
    • Biohaven Pharmaceuticals
    • F. Hoffmann-La Roche Ltd
    • Cytokinetics
    • Scholar Rock, Inc.
    • PTC Therapeutics
    • NMD PHARMA A/S
    • Astellas Pharma Inc.

第 11 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查属性
  • 调查先决条件

Global Spinal Muscular Atrophy Treatment Market is valued at approximately USD 3.88 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Spinal muscular atrophy (SMA) is a type of genetic disease that gradually destroys motor neurons that are the spinal cord and nerve cells in the brain stem. It also affects vital skeletal muscle activity including breathing, walking, speaking, and swallowing, which leads to muscle weakness and atrophy. The growing awareness regarding novel therapies, rising government support, coupled with increasing healthcare expenditure is primary factors that are fostering market growth across the globe.

The prevalence of spinal muscular atrophy is on the rise which is directly associated with the market demand across the globe. The National Organization for Rare Disorders (NORD) estimates that approximately 1 in 10,000 people worldwide suffer with spinal muscular atrophy (SMA). Likewise, according to the Spinal Muscular Atrophy Foundation, the condition is expected to affect 1 in every 6,000 to 10,000 newborns worldwide. Therefore, the growing incidences of the disorder are actively contributing to market demand, which, in turn, fosters the growth of the market. Moreover, the introduction of new product with high efficacies, as well as growing R&D investments are presenting various lucrative opportunities over the forecasting years. However, the high costs associated with the approved products and the dearth of skilled professionals are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Spinal Muscular Atrophy Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing spending on treatment products and the rising incidence of SMA disorders among the population. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as rising target populations, increasing expenditure on healthcare services, and geographic expansion of key players in the market space.

Major market players included in this report are:

  • Biogen
  • Novartis AG
  • Ionis Pharmaceuticals Inc.
  • Biohaven Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Cytokinetics
  • Scholar Rock, Inc.
  • PTC Therapeutics
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

Recent Developments in the Market:

  • In January 2022, Biogen and Ionis Pharmaceuticals, Inc., declare that the companies entered into licensing agreement with the aim of developing another experimental drug BIIB115 (an antisense oligonucleotide) to cure of patients with SMA. BIIB115 is an experimental preclinical-stage drug. The objective of this agreement is to expand Biogen's SMA drug portfolio.
  • In May 2019, Novartis AG announced that its Zolgensma (onasemnogene abeparvovec-xioi) received an approval from the U.S. FDA for the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).

Global Spinal Muscular Atrophy Treatment Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Disease Type, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Nusinersen
  • Onasemnogen Abeparvovec

By Disease Type:

  • Type 1 SMA
  • Type 2 SMA
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Spinal Muscular Atrophy Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Spinal Muscular Atrophy Treatment Market, by Product, 2019-2029 (USD Billion)
    • 1.2.3. Spinal Muscular Atrophy Treatment Market, by Disease Type, 2019-2029 (USD Billion)
    • 1.2.4. Spinal Muscular Atrophy Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Spinal Muscular Atrophy Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Spinal Muscular Atrophy Treatment Market Dynamics

  • 3.1. Spinal Muscular Atrophy Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing awareness regarding novel therapies
      • 3.1.1.2. Growing prevalence of spinal muscular atrophy
    • 3.1.2. Market Challenges
      • 3.1.2.1. High costs associated with the approved products
      • 3.1.2.2. Dearth of skilled professionals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Introduction of new product with high efficacies
      • 3.1.3.2. Growing R&D investments

Chapter 4. Global Spinal Muscular Atrophy Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Spinal Muscular Atrophy Treatment Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Spinal Muscular Atrophy Treatment Market by Product, Performance - Potential Analysis
  • 6.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
  • 6.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 6.4.1. Nusinersen
    • 6.4.2. Onasemnogen Abeparvovec

Chapter 7. Global Spinal Muscular Atrophy Treatment Market, by Disease Type

  • 7.1. Market Snapshot
  • 7.2. Global Spinal Muscular Atrophy Treatment Market by Disease Type, Performance - Potential Analysis
  • 7.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Disease Type 2019-2029 (USD Billion)
  • 7.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 7.4.1. Type 1 SMA
    • 7.4.2. Type 2 SMA
    • 7.4.3. Others

Chapter 8. Global Spinal Muscular Atrophy Treatment Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Spinal Muscular Atrophy Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Others

Chapter 9. Global Spinal Muscular Atrophy Treatment Market, Regional Analysis

  • 9.1. Spinal Muscular Atrophy Treatment Market, Regional Market Snapshot
  • 9.2. North America Spinal Muscular Atrophy Treatment Market
    • 9.2.1. U.S. Spinal Muscular Atrophy Treatment Market
      • 9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Disease Type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Spinal Muscular Atrophy Treatment Market
  • 9.3. Europe Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.3.1. U.K. Spinal Muscular Atrophy Treatment Market
    • 9.3.2. Germany Spinal Muscular Atrophy Treatment Market
    • 9.3.3. France Spinal Muscular Atrophy Treatment Market
    • 9.3.4. Spain Spinal Muscular Atrophy Treatment Market
    • 9.3.5. Italy Spinal Muscular Atrophy Treatment Market
    • 9.3.6. Rest of Europe Spinal Muscular Atrophy Treatment Market
  • 9.4. Asia-Pacific Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.4.1. China Spinal Muscular Atrophy Treatment Market
    • 9.4.2. India Spinal Muscular Atrophy Treatment Market
    • 9.4.3. Japan Spinal Muscular Atrophy Treatment Market
    • 9.4.4. Australia Spinal Muscular Atrophy Treatment Market
    • 9.4.5. South Korea Spinal Muscular Atrophy Treatment Market
    • 9.4.6. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
  • 9.5. Latin America Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.5.1. Brazil Spinal Muscular Atrophy Treatment Market
    • 9.5.2. Mexico Spinal Muscular Atrophy Treatment Market
    • 9.5.3. Rest of Latin America Spinal Muscular Atrophy Treatment Market
  • 9.6. Rest of The World Spinal Muscular Atrophy Treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Biogen
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Novartis AG
    • 10.2.3. Ionis Pharmaceuticals Inc.
    • 10.2.4. Biohaven Pharmaceuticals
    • 10.2.5. F. Hoffmann-La Roche Ltd
    • 10.2.6. Cytokinetics
    • 10.2.7. Scholar Rock, Inc.
    • 10.2.8. PTC Therapeutics
    • 10.2.9. NMD PHARMA A/S
    • 10.2.10. Astellas Pharma Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Spinal Muscular Atrophy Treatment Market, report scope
  • TABLE 2. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Product 2019-2029 (USD Billion)
  • TABLE 4. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Disease Type 2019-2029 (USD Billion)
  • TABLE 5. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 6. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Spinal Muscular Atrophy Treatment Market
  • TABLE 71. List of primary sources, used in the study of global Spinal Muscular Atrophy Treatment Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Spinal Muscular Atrophy Treatment Market, research methodology
  • FIG 2. Global Spinal Muscular Atrophy Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Spinal Muscular Atrophy Treatment Market, key trends 2021
  • FIG 5. Global Spinal Muscular Atrophy Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Spinal Muscular Atrophy Treatment Market, porters 5 force model
  • FIG 7. Global Spinal Muscular Atrophy Treatment Market, pest analysis
  • FIG 8. Global Spinal Muscular Atrophy Treatment Market, value chain analysis
  • FIG 9. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Spinal Muscular Atrophy Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Spinal Muscular Atrophy Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable